CRS is a severe adverse reaction in CAR-T cell therapy (24), representing a severe systemic inflammatory response syndrome triggered by the activation of immune cells and the massive release of cytokines such as tumor necrosis factor-α (TNF-α), interleukins (ILs), and interferons (IFNs) (20, 25).Severe CRS can lead to organ dysfunction. The gene discussed is TNF; the disease is congenital rubella syndrome.